Take Homes in CAR T-cell Therapy

Take Homes in CAR T-cell Therapy

Source:

Majzner, RG et al. Abstract 556. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.

Disclosures: Locke reports holding a scientific advisory role for Allogene, Celgene, GammaDelta Therapeutics, Kite, Novartis and Wugen; and acting as consultant with grant options for Cellular Biomedicine Group Inc.
December 10, 2020
1 min watch
Save

VIDEO: CAR T-cell construct will improve efficacy for CD58 loss, mutation

Source:

Majzner, RG et al. Abstract 556. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.

Disclosures: Locke reports holding a scientific advisory role for Allogene, Celgene, GammaDelta Therapeutics, Kite, Novartis and Wugen; and acting as consultant with grant options for Cellular Biomedicine Group Inc.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Researchers successfully created a CAR T-cell construct to signal CD58 mutation or loss in patients with large B cell lymphomas, according to a presentation from the ASH Annual Meeting and Exposition.

“This is a great example of how we can use clinical data from patients treated with CAR T-cell therapy and discover a new mechanism that's leading to decreased efficacy and then design new CAR T-cell constructs that at least in vivo and in vitro, could work better in some of these patients,” Frederick Locke, MD, co-leader of the Immunology Program at Moffitt Cancer Center, told Healio in a video interview.